Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines

References

• Centers for Disease Control. Ten great public health achievements – United States, 1900–1999. MMWR (1999).
   Google Scholar
• Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20, 63–75 (2001).
   PubMed Web of Science ®Google Scholar
• Ball TM, Serwint JR. Missed opportunities for vaccination and the delivery of preventive care. Arch. Pediatr. Adolesc. Med. 150, 858–861 (1996).
   PubMedGoogle Scholar
• Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics 5, 417–427 (2004).
   PubMed Web of Science ®Google Scholar
• Dhiman N, Bonilla R, O’Kane D, Poland GA. Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 20, 22–30 (2002).
   Web of Science ®Google Scholar
• De Groot AS, Sbai H, Aubin CS, McMurry J, Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. 80, 255–269 (2002).
   PubMed Web of Science ®Google Scholar
• Dhiman N, Bonilla RG, Jacobson RM, O’Kane D, Poland GA. Differential HLA gene expression in measles vaccine seropositive and seronegative subjects: a pilot study. Scand. J. Infect. Dis. 35, 332–336 (2003).
   PubMed Web of Science ®Google Scholar
• Hayney MS, Poland GA, Jacobson RM et al. Relationship of HLA-DQA1 alleles and humoral antibody following measles vaccination. Int. J. Infect. Dis. 2, 143–146 (1998).
   PubMedGoogle Scholar
• Hayney MS, Poland GA, Jacobson RM, Schaid DJ, Lipsky JJ. The influence of the HLA-DRB1*13 allele on measles vaccine response. J. Invest. Med. 44, 261–263 (1996).
   PubMed Web of Science ®Google Scholar
• Jacobson RM, Poland GA. The genetic basis for measles vaccine failure. Acta Paediatr. 445(Suppl.), 43–47 (2004).
   Google Scholar
• Jacobson RM, Poland GA, Vierkant RA et al. The association of class I HLA alleles and antibody levels following a single dose of measles vaccine. Hum. Immunol. 64, 103–109 (2003).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum. Immunol. 65, 1506–1515 (2004).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles–mumps–rubella-II vaccination. J. Infect. Dis. 191, 515–519 (2005).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz SV, Jacobsen SJ, Poland GA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 22, 1914–1920 (2004).
   PubMed Web of Science ®Google Scholar
• Poland GA, Jacobson RM. The genetic basis for variation in antibody response to vaccines. Curr. Opin. Pediatr. 10, 208–215 (1998).
   PubMed Web of Science ®Google Scholar
• Poland GA, Jacobson RM, Schaid DJ, Moore SB, Jacobsen SJ. The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Vaccine 16, 1869–1871 (1998).
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Jacobson RM et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 20, 430–438 (2001).
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Ovsyannikova IG, Jacobson RM et al. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J. Infect. Dis. 185, 1545–1549 (2002).
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Schaid DJ, Vierkant RA et al. Associations between measles antibody levels and the protein structure of class II human leukocyte antigens. Hum. Immunol. 64, 696–707 (2003).
   PubMed Web of Science ®Google Scholar
• Poland GA. Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am. J. Hum. Genet. 62, 215–220 (1998).
   PubMed Web of Science ®Google Scholar
• Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506–512 (1987).
   PubMed Web of Science ®Google Scholar
• Huston DP. The biology of the immune system. JAMA 278, 1804–1814 (1997).
   PubMed Web of Science ®Google Scholar
• Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178–228 (1995).
   PubMed Web of Science ®Google Scholar
• Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716–719 (1994).
   PubMed Web of Science ®Google Scholar
• Khalil-Daher I, Boisgérault F, Feugeas JP, Tieng V, Toubert A, Charron D. Naturally processed peptides from HLA-DQ7(a1*0501-b1*0301): influence of both a and b chain polymorphism in the HLA-DQ peptide binding specificity. Eur. J. Immunol. 28, 3840–3849 (1998).
   PubMed Web of Science ®Google Scholar
• Klein J, Sato A. The HLA system. First of two parts. N. Engl. J. Med. 343, 702–709 (2000).
   PubMed Web of Science ®Google Scholar
• Klein J, Sato A. The HLA system. Second of two parts. N. Engl. J. Med. 343, 782–786 (2000).
   PubMed Web of Science ®Google Scholar
• Trowsdale J, Ragoussis J, Campbell RD. Map of the human MHC. Immunol. Today 12, 443–446 (1991).
   PubMedGoogle Scholar
• Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol. Cell Biol. 77, 304–311 (1999).
   PubMed Web of Science ®Google Scholar
• Romagnani S. Th1/Th2 cells. Inflamm. Bowel Dis. 5, 285–294 (1999).
   PubMed Web of Science ®Google Scholar
• Ward BJ, Griffin DE. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin. Immunol. Immunopathol. 67, 171–177 (1993).
   PubMedGoogle Scholar
• Chesler DA, Reiss CS. The role of IFN-γ in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 13, 441–454 (2002).
   PubMed Web of Science ®Google Scholar
• Gans HA, Maldonado Y, Yasukawa LL et al. IL-12, IFN-γ, and T cell proliferation to measles in immunized infants. J. Immunol. 162, 5569–5575 (1999).
   PubMed Web of Science ®Google Scholar
• Paludan SR. Interleukin-4 and interferon-g: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol. 48, 459–468 (1998).
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann. Rev. Immunol. 16, 111–135 (1998).
   PubMed Web of Science ®Google Scholar
• Neuberger MS, Ehrenstein MR, Rada C et al. Memory in the B-cell compartment: antibody affinity maturation. Philosoph. Trans. Royal Soc. B: Biological Sci. 355, 357–360 (2000).
   Web of Science ®Google Scholar
• Welsh RM, Selin LK, Szomolanyi-Tsuda E. Immunological memory to viral infections. Ann. Rev. Immunol. 22, 711–743 (2004).
   PubMed Web of Science ®Google Scholar
• Fehr T, Naim HY, Bachmann MF et al. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nature Med. 4, 945–948 (1998).
   PubMed Web of Science ®Google Scholar
• Milich DR. Synthetic T and B cell recognition sites: implications for vaccine development. Adv. Immunol. 45, 195–282 (1989).
   PubMed Web of Science ®Google Scholar
• Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol. Rev. 18, 99–117 (1996).
   PubMed Web of Science ®Google Scholar
• Burton DR. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2, 706–713 (2002).
   PubMed Web of Science ®Google Scholar
• Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103, 133–138 (2004).
   PubMed Web of Science ®Google Scholar
• Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild type virus. J. Clin. Microbiol. 24, 157–160 (1986).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181, 1133–1137 (2000).
   PubMed Web of Science ®Google Scholar
• Palache AM. Antibody response after influenza immunization with various vaccine doses: A double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 11, 3–9 (1993).
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 70, 767–777 (1972).
   PubMedGoogle Scholar
• Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 270, 1956–1961 (1994).
   Web of Science ®Google Scholar
• Foster DA, Talsma A, Furumoto-Dawson A et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am. J. Epidemiol. 136, 296–307 (1992).
   PubMed Web of Science ®Google Scholar
• Mullooly J, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost–effectiveness in a health maintenance organization. Ann. Intern. Med. 121, 947–952 (1994).
   PubMed Web of Science ®Google Scholar
• Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 18, 957–1030 (2000).
   PubMed Web of Science ®Google Scholar
• Beyer WEP, de Bruijn IA, Palache AM, Westendorp RGJ, Osterhaus ADME. Protection against influenza after annually repeated vaccination. A meta-analysis of serologic and field studies. Arch. Intern. Med. 159, 182–188 (1999).
   PubMedGoogle Scholar
• Plotkin SA. Rubella Vaccine. In: Vaccines (Third Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders, PA, USA, 409–440 (1999).
   Google Scholar
• O’hea S, Best JM, Banatvala JE. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J. Infect. Dis. 148, 639–647 (1983).
   PubMed Web of Science ®Google Scholar
• Schwarzer S, Reibel S, Lang AB et al. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 16, 298–304 (1998).
   PubMed Web of Science ®Google Scholar
• Fedson DS, Shapiro ED, LaForce FM et al. Pneumococcal vaccine after 15 years of use. Another view. Arch. Intern. Med. 154, 2531–2535 (1994).
   PubMedGoogle Scholar
• Orenstein WA, Albrecht P, Herrmann KL, Bernier R, Bart KJ, Rovira EZ. The plaque-neutralization test as a measure of prior exposure to measles virus. J. Infect. Dis. 155, 146–149 (1987).
   PubMed Web of Science ®Google Scholar
• Chen RT, Markowitz LE, Albrecht P et al. Measles antibody: Reevaluation of protective titers. J. Infect. Dis. 162, 1036–1042 (1990).
   PubMed Web of Science ®Google Scholar
• Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP. Protection provided by hepatitis B vaccine in a Yupik Eskimo population – seven-year results. Arch. Intern. Med. 151, 1634–1636 (1991).
   PubMedGoogle Scholar
• West DJ, Calandra GR. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14, 1019–1027 (1996).
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Rehermann B, Koutsoukos M et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 23, 2591–2601 (2005).
   PubMed Web of Science ®Google Scholar
• Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 14, 735–746 (1996).
   PubMed Web of Science ®Google Scholar
• O’Ryan ML, Matson DO, Estes MK, Pickering LK. Antirotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J. Infect. Dis. 169, 504–511 (1994).
   PubMed Web of Science ®Google Scholar
• Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J. Infect. Dis. 170, S24–S31 (1994).
   PubMedGoogle Scholar
• Poland GA, Jacobson RM. Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. Arch. Intern. Med. 154, 1815–1820 (1994).
   PubMedGoogle Scholar
• Poland GA. Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. Vaccine 17, 1719–1725 (1999).
   PubMed Web of Science ®Google Scholar
• Pabst HF, Spady DW, Carson MM, Krezolek MP, Barreto L, Wittes RC. Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine 17, 1910–1918 (1999).
   PubMed Web of Science ®Google Scholar
• Pabst HF, Spady DW, Carson MM, Stelfox HT, Beeler JA, Krezolek MP. Kinetics of immunologic responses after primary MMR vaccination. Vaccine 15, 10–14 (1997).
   PubMed Web of Science ®Google Scholar
• Ward BJ, Boulianne N, Ratnam S, Guiot M-C, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: Demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J. Infect. Dis. 172, 1591–1595 (1995).
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of T-cell immunity: Implications for vaccine strategies against intracellular pathogens. Exp. Rev. Vaccines 3, 23–34 (2003).
   Google Scholar
• Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J. Infect. Dis. 168, 275–281 (1993).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Reid KC, Jacobson RM, Oberg AL, Klee GG, Poland GA. Cytokine production patterns and antibody response to measles vaccine.Vaccine 21, 3946–3953 (2003).
   PubMed Web of Science ®Google Scholar
• Howe RC, Dhiman N, Ovsyannikova IG, Poland GA. Induction of CD4 T cell proliferation and Th1-like cytokine responses in vitro to measles virus. Clin. Exp. Immunol. 140, 333–342 (2005).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Jacobson RM, Ryan JE et al. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 56, 798–807 (2005).
   Google Scholar
• Schnorr J-J, Cutts FT, Wheeler JG et al. Immune modulation after measles vaccination of 6–9 months old Bangladeshi infants. Vaccine 19, 1503–1510 (2001).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global measles mortality reduction and regional elimination strategic plan 2001–2005. (2001).
   Google Scholar
• World Health Organization. Proceedings of the Conference on Global Disease Elimination and Eradication as Public Health Strategies. Atlanta, GA, USA, 23–25 February (2000).
   Google Scholar
• Tan P-L, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV. Twin studies of immunogenicity-determining the genetic contribution to vaccine failure. Vaccine 19, 2434–2439 (2001).
   PubMed Web of Science ®Google Scholar
• Hohler T, Reuss E, Evers N et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360, 991–995 (2002).
   PubMed Web of Science ®Google Scholar
• Newport MJ, Goetghebuer T, Weiss HA et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5, 122–129 (2004).
   PubMed Web of Science ®Google Scholar
• Kubba AK, Taylor P, Graneek B, Strobel S. Non-responders to hepatitis B vaccination: a review. Commun. Dis. Public Health 6, 106–112 (2003).
   PubMedGoogle Scholar
• Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med. 175, 495–502 (1992).
   PubMed Web of Science ®Google Scholar
• Mineta M, Tanimura M, Tana T, Yssel H, Kashiwagi S, Sasazuki T. Contribution of HLA class I and class II alleles to the regulation of antibody production to hepatitis B surface antigen in humans. Int. Immunol. 8, 525–531 (1996).
   PubMed Web of Science ®Google Scholar
• Langö-Warensjö A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 52, 374–380 (1998).
   PubMedGoogle Scholar
• Hsu H-Y, Chang M-H, Ho H-N et al. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 11, 1437–1440 (1993).
   PubMed Web of Science ®Google Scholar
• Walker M, Szmuness W, Stevens C, Rubinstein P. Genetics of antiHBs responsiveness. 1. HLA-DR7 and non-responsiveness to hepatitis vaccination. Transfusion 21, 601 (1981).
   Web of Science ®Google Scholar
• Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 51, 593–604 (1998).
   PubMed Web of Science ®Google Scholar
• Caillat-Zucman S, Gimenez J-J, Wambergue F et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int. 53, 1626–1630 (1998).
   PubMed Web of Science ®Google Scholar
• Martinetti M, De Silvestri A, Belloni C et al. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin. Immunol. 97, 234–240 (2000).
   PubMed Web of Science ®Google Scholar
• Alper CA, Kruskall MS, Marcus-Bagley D et al. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321, 708–712 (1989).
   PubMed Web of Science ®Google Scholar
• Caillat-Zucman S, Gimenez J-J, Albouze G et al. HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients. Kidney Int. 43, S157–S160 (1993).
   Google Scholar
• Alper CA. The human immune response to hepatitis B surface antigen. Exp. Clin. Immunogenet. 12, 171–181 (1995).
   PubMedGoogle Scholar
• Hatae K, Kimura A, Okubo R et al. Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur. J. Immunol. 22, 1899–1905 (1992).
   PubMed Web of Science ®Google Scholar
• McDermott AB, Cohen SBA, Zuckerman JN, Madrigal JA. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 17, 330–339 (1999).
   PubMed Web of Science ®Google Scholar
• McDermott AB, Zuckerman JN, Sabin CA, Marsh SGE, Madrigal JA. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 50, 8–14 (1997).
   PubMedGoogle Scholar
• Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39, 978–988 (2004).
   PubMed Web of Science ®Google Scholar
• Lindemann M, Barsegian V, Siffert W, Ferencik S, Roggendorf M, Grosse-Wilde H. Role of G-protein β3 subunit C825T and HLA class II polymorphisms in the immune response after HBV vaccination. Virology 297, 245–252 (2002).
   PubMed Web of Science ®Google Scholar
• Hohler T, Stradmann-Bellinghausen B, Starke R et al. C4A deficiency and nonresponse to hepatitis B vaccination. J. Hepatol. 37, 387–392 (2002).
   PubMed Web of Science ®Google Scholar
• Schuenke KW, Cook RG, Rich RR. Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Hum. Immunol. 59, 783–793 (1998).
   PubMed Web of Science ®Google Scholar
• Gelder CM, Lambkin R, Hart KW et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J. Infect. Dis. 185, 114–117 (2002).
   PubMed Web of Science ®Google Scholar
• Lambkin R, Novelli P, Oxford J, Gelder C. Human genetics and responses to influenza vaccination: clinical implications. Am. J. Pharmacogenomics 4, 293–298 (2004).
   PubMedGoogle Scholar
• Gelder CM, Lamb JR, Askonas BA. Human CD4+ T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J. Virol. 70, 4787–4790 (1996).
   PubMed Web of Science ®Google Scholar
• Saririan K, Wali A, Almeida RP, Russo C. Increased serum HLA class I molecule levels in elderly human responders to influenza vaccination. Tissue Antigens 42, 9–13 (1993).
   PubMedGoogle Scholar
• Saririan KK, Contini P, Indiveri F, Gross PA, Russo C. Serum HLA class I levels in elderly humans. Utilization in following the response to influenza vaccine. Hum. Immunol. 40, 202–209 (1994).
   PubMed Web of Science ®Google Scholar
• Brunell PA, Weigle K, Murphy D, Shehab Z, Cobb E. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA 250, 1409–1412 (1983).
   PubMed Web of Science ®Google Scholar
• Poland GA, Jacobson RM, Colbourne SA et al. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 17, 1525–1531 (1999).
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Johnson KL, Muddiman DC, Vierkant RA, Poland GA. Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides. J. Virol. 78, 42–51 (2004).
   PubMed Web of Science ®Google Scholar
• Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 47, 1–57 (1998).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 38, 1–18 (1989).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Measles eradication: Recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR 46, 1–20 (1997).
   PubMedGoogle Scholar
• St. Sauver JL, Dhiman N, Ovsyannikova IG et al. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine. Hum. Immunol. 66, 788–798 (2005).
   PubMed Web of Science ®Google Scholar
• Mitchell LA, Zhang T, Tingle AJ. Differential antibody responses to rubella virus infection in males and females. J. Infect. Dis. 166, 1258–1265 (1992).
   PubMed Web of Science ®Google Scholar
• Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. Br. Med. J. 304, 1075–1078 (1992).
   PubMed Web of Science ®Google Scholar
• Mitchell LA. Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation. J. Med. Microbiol. 48, 1075–1080 (1999).
   PubMed Web of Science ®Google Scholar
• Hsia S, Howell DN, Amos DB, Woodbury MA. Studies of viral antibody responses among Amish families. J. Immunol. 118, 1659–1664 (1977).
   PubMed Web of Science ®Google Scholar
• Hyoty H, Rasanen L, Lehto M et al. Cell-mediated and humoral immunity to mumps virus antigen. Acta. Pathol. Microbiol. Immunol. Scand. 94, 201–206 (1986).
   Google Scholar
• Dawson DV, Ozgur M, Sari K, Ghanayem M, Kostyu DD. Ramifications of HLA class I polymorphism and population genetics for vaccine development. Genet. Epidemiol. 20, 87–106 (2001).
   PubMed Web of Science ®Google Scholar
• Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med. 2, 405–411 (1996).
   PubMed Web of Science ®Google Scholar
• Mellins E, Woelfel M, Pious D. Importance of HLA-DQ and -DP restriction elements in T-cell responses to soluble antigens: mutational analysis. Hum. Immunol. 18, 211–223 (1987).
   PubMed Web of Science ®Google Scholar
• Danke NA, Kwok WW. HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J. Immunol. 171, 3163–3169 (2003).
   PubMed Web of Science ®Google Scholar
• Ou D, Mitchell LA, Décarie D, Tingle AJ, Nepom GT. Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype. Hum. Immunol. 59, 149–157 (1998).
   PubMed Web of Science ®Google Scholar
• Haynes BF, Yasutomi Y, Torres JV et al. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: An HLA-based vaccine strategy. Trans. Assoc. Am. Physicians 106, 33–41 (1993).
   PubMedGoogle Scholar
• Doolan DL, Southwood S, Chesnut R et al. HLA-DR promiscuous T cell epitopes from Plasmodium falciparum ore-erythrocytic-state antigens restricted by multiple HLA Class II alleles. J. Immunol. 165, 1123–1137 (2000).
   PubMed Web of Science ®Google Scholar
• Nardin EH, Oliveira GA, Calvo-Calle JM et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182, 1486–1496 (2000).
   PubMed Web of Science ®Google Scholar